Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Rahul Naskar has years of experience writing news and features related to Android, phones, and apps. Outside the tech world, he follows global events and developments shaping the world of geopolitics.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

TikTok, recently on the brink of a US ban, is a service that needs no introduction; it has become one of the most ubiquitous social media platforms and video viewing apps in the world, with the ...

The Magic 8 Pro has already made its debut internationally, but Honor is now expanding the lineup with the Magic 8 Lite. The latter just made its debut with a surprisingly big battery and a durable ...

HONOR Magic 8 Lite has been launched as the cheapest model in the series. The phone gets a whopping 7,500mAh battery that should be pretty hard to kill. It features the Snapdragon 6 Gen 4, an OLED ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

As the global AI wave pushes computing infrastructure into the megawatt (MW) era, Taiwan's Lite-On Technology is moving quickly to meet the demands of next-generation AI factories. Jin-tsai Wang, ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...